Posted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals.
Europe is adapting to high cost specialised treatments reaching the market via accelerated access initiatives, including cell and gene therapies – but models are still in their infancy, and a co-ordinated approach to value across the region would benefit all sides.
That was the message from a panel of industry leaders in the field at a conference in London last week, who shared the platform with payers to discuss how advanced therapy medicinal products can gain market access.
